Merck Dividenden en inkoop

Dividend criteriumcontroles 5/6

Merck is een dividendbetalend bedrijf met een huidig rendement van 3.16% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

3.2%

Dividendrendement

0.4%

Terugkoop Rendement

Totaal aandeelhoudersrendement	3.6%
Toekomstig dividendrendement	3.4%
Dividendgroei	-1.2%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	US$3.080
Uitbetalingsratio	63%

Recente updates van dividend en inkoop

Recent updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Het dividend per aandeel van MRK is de afgelopen 10 jaar stabiel gebleven.

Groeiend dividend: De dividendbetalingen van MRK zijn de afgelopen 10 jaar gestegen.

Dividendrendement versus markt

Merck Dividendrendement versus markt

Hoe verhoudt MRK dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (MRK)	3.2%
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.3%
Gemiddelde industrie (Pharmaceuticals)	2.5%
Analist prognose (MRK) (tot 3 jaar)	3.4%

Opmerkelijk dividend: Het dividend van MRK ( 3.16% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de US markt ( 1.38% ).

Hoog dividend: Het dividend MRK ( 3.16% ) is laag vergeleken met de top 25% van dividendbetalers in de US markt ( 4.32% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn redelijke payout ratio ( 63.4% ) worden de dividendbetalingen van MRK gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijke cash payout ratio ( 52.5% ) worden de dividendbetalingen van MRK gedekt door kasstromen.

Merck Dividenden en inkoop

Dividend criteriumcontroles 5/6

Belangrijke informatie

Recente updates van dividend en inkoop

Upcoming dividend of US$0.77 per share

Recent updates

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck: An Undervalued Dividend Machine

Third quarter 2024 earnings: EPS misses analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Merck Is At Support And Should Go Higher (Technical Analysis)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend